Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01172535 · ClinicalTrials.gov registry record · Phase 2
A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines
A Phase 2 study of HIV, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
- 19
- Study locations
NCT01172535 is a Phase 2 study of HIV that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 97 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (78% lower). The trial reports 19 study locations across 10 states.
The verdict
NCT01172535, a Phase 2 study of HIV, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
- 19
- Study locations
Study Summary
Treatment of children and infants with HIV requires modification of medication dosing according to a child's specific weight. For lopinavir/ritonavir (LPV/r), a second line treatment option that is increasingly necessary due to infant drug resistance, this dosing is often complicated and impractical in busy clinical settings. To address this, the World Health Organization (WHO) has released a simplified dosing table based on infant weight bands. This study will evaluate the absorption, safety, and tolerance of LPV/r in infants when dosed according to the new WHO guidelines.
Conditions Studied
Interventions
- DRUG Lopinavir/ritonavir
Study Locations (19)
Other
- Hospital Federal dos Servidores do Estado NICHD CRS - Rio de Janeiro
- Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS - Rio de Janeiro
- Hosp. Geral De Nova Igaucu Brazil NICHD CRS - Rio de Janeiro
- Inst de Infectologia Emilio Ribas Sao Paulo Brazil NICHD CRS - São Paulo
- Univ. of Sao Paulo Brazil NICHD CRS - São Paulo
- Prapokklao Hosp. CRS - Chanthaburi
- Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS - Chiang Mai
- Chiangrai Prachanukroh Hospital CRS - Chiangrai
- Chonburi Hosp. CRS - Chon Buri
- Phayao Provincial Hosp. CRS - Phayao
California
- University of California, UC San Diego CRS - La Jolla
Colorado
- Univ. of Colorado Denver NICHD CRS - Aurora
Massachusetts
- Boston Medical Center Ped. HIV Program NICHD CRS - Boston
Minas Gerais
- SOM Federal University Minas Gerais Brazil NICHD CRS - Belo Horizonte
Rio Grande do Sul
- Hosp. Santa Casa Porto Alegre Brazil NICHD CRS - Porto Alegre
Gauteng
- Shandukani CRS - Johannesburg
Western Cape
- Family Clinical Research Unit (FAM-CRU) CRS - Tygerberg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01172535
The ClinicalTrials.gov registry entry for NCT01172535 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (78% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Lopinavir/ritonavir is the first listed.
NCT01172535 reports 19 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT01172535 about?
NCT01172535 is a clinical study titled "A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines". Treatment of children and infants with HIV requires modification of medication dosing according to a child's specific weight. For lopinavir/ritonavir (LPV/r), a second line treatment option that is increasingly necessary due to infant drug resistance, this dosing is often complicated and impractical...
What is the current status of trial NCT01172535?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2010-11. Estimated completion is 2013-12.
What conditions does trial NCT01172535 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT01172535?
The interventions under investigation include: Lopinavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT01172535?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01172535 being conducted?
This trial has 19 study locations across California, Colorado, Massachusetts, Minas Gerais, Rio Grande do Sul. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Improving Physical Ability and Cellular Senescence Elimination in HIV
RECRUITING · Phase 2
-
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
RECRUITING · Phase 2
-
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
RECRUITING · Phase 2
-
A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.